Featured Research

from universities, journals, and other organizations

Study Finds Continued Reduction In Breast Cancer Incidence Associated With Longer Use Of Raloxifene

Date:
December 14, 2004
Source:
Journal Of The National Cancer Institute
Summary:
Raloxifene (Evista) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, according to a new study in the December 1 issue of the Journal of the National Cancer Institute.

Raloxifene (Evista) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, according to a new study in the December 1 issue of the Journal of the National Cancer Institute.

The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that, in postmenopausal women with osteoporosis, 4 years of treatment with raloxifene was associated with a 72% reduction in breast cancer incidence compared with placebo. The Continuing Outcomes Relevant to Evista (CORE) trial was designed to examine the effect of an additional 4 years of treatment with raloxifene in the same group of women.

In the CORE trial, more than 4,000 women who had been part of the MORE trial continued taking either 60 mg/day of raloxifene, if they had been assigned to the raloxifene group in the MORE trial, or a placebo, if they had been assigned to the placebo group.

Silvana Martino, D.O., of the Cancer Institute Medical Group in Santa Monica, Calif., and colleagues report that, after the 4 years of the CORE trial, incidence of invasive breast cancer for women taking raloxifene was reduced by 59% compared with women taking the placebo, and incidence of estrogen-receptor (ER)-positive invasive breast cancer was reduced by 66%. Over the entire 8 years of MORE and CORE, the incidence of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66% and 76%, respectively. There was no difference between the two groups in incidence of either ER-negative invasive breast cancer or noninvasive breast cancer. In both the MORE and CORE trials, there was a twofold increase in venous thromboembolic events, such as pulmonary embolism, among women taking raloxifene.

"[T]hese data demonstrate that the incidence of ER-positive invasive breast cancer continues to be reduced through 8 years of raloxifene treatment in postmenopausal women with osteoporosis," the authors write. "The effect of raloxifene on breast cancer incidence is currently being evaluated in postmenopausal women at high risk for heart disease in the Raloxifene Use for The Heart (RUTH) trial and in postmenopausal women at high risk for breast cancer in the STAR [Study of Tamoxifen and Raloxifene] trial."

In an editorial, Powel Brown, M.D., Ph.D., of the Baylor College of Medicine in Houston, and colleagues note that the effect of raloxifene treatment in the CORE trial may be confounded by several factors, but write that the results of the CORE and MORE trials support the conclusion that raloxifene reduces the risk of breast cancer. However, the authors write, "For women without osteoporosis who are at high risk of breast cancer, tamoxifen, in our opinion, remains the 'gold standard' chemoprevention agent to reduce the risk of breast cancer in high-risk pre- and postmenopausal women. We anticipate that the results of several large-scale chemoprevention trials will help clarify the role of raloxifene, as well as other hormonal agents, for breast cancer prevention."

###

#

Citations:# Article: Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. J Natl Cancer Inst 2004;96:1751–61.# Editorial: Kalidas M, Hilsenbeck S, Brown P. Defining the Role of Raloxifene for the Prevention of Breast Cancer. J Natl Cancer Inst 2004;96:1731–33.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.


Story Source:

The above story is based on materials provided by Journal Of The National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal Of The National Cancer Institute. "Study Finds Continued Reduction In Breast Cancer Incidence Associated With Longer Use Of Raloxifene." ScienceDaily. ScienceDaily, 14 December 2004. <www.sciencedaily.com/releases/2004/12/041201001055.htm>.
Journal Of The National Cancer Institute. (2004, December 14). Study Finds Continued Reduction In Breast Cancer Incidence Associated With Longer Use Of Raloxifene. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2004/12/041201001055.htm
Journal Of The National Cancer Institute. "Study Finds Continued Reduction In Breast Cancer Incidence Associated With Longer Use Of Raloxifene." ScienceDaily. www.sciencedaily.com/releases/2004/12/041201001055.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins